Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension.
作者信息
Sofer Avraham, Lee Seyoung, Papangeli Irinna, Adachi Takaomi, Hwangbo Cheol, Comhair Suzy, DaSilva-Jardine Paul, Kim Jongmin, Schwarz John J, Erzurum Serpil C, Chun Hyung J
机构信息
1 Yale University School of Medicine New Haven, Connecticut.
2 Cleveland Clinic Cleveland, Ohio.
出版信息
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1345-1348. doi: 10.1164/rccm.201805-0817LE.
Abstract
摘要
相似文献
1
Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension.
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1345-1348. doi: 10.1164/rccm.201805-0817LE.
2
The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro.
J Cell Sci. 2015 Nov 1;128(21):3961-76. doi: 10.1242/jcs.170357. Epub 2015 Sep 24.
3
The black sheep of class IIa: HDAC7 SIKens the heart.
J Clin Invest. 2020 Jun 1;130(6):2811-2813. doi: 10.1172/JCI137074.
4
MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.
Mol Cell Biol. 2013 Nov;33(22):4473-91. doi: 10.1128/MCB.01050-13. Epub 2013 Sep 16.
5
Converse role of class I and class IIa HDACs in the progression of atrial fibrillation.
J Mol Cell Cardiol. 2018 Dec;125:39-49. doi: 10.1016/j.yjmcc.2018.09.010. Epub 2018 Oct 12.
6
Class IIa histone deacetylases and myocyte enhancer factor 2 proteins regulate the mesenchymal-to-epithelial transition of somatic cell reprogramming.
J Biol Chem. 2013 Apr 26;288(17):12022-31. doi: 10.1074/jbc.M113.460766. Epub 2013 Mar 6.
7
Transcriptional and posttranscriptional repression of histone deacetylases by docosahexaenoic acid in macrophages.
J Nutr Biochem. 2018 Jul;57:162-169. doi: 10.1016/j.jnutbio.2018.03.002. Epub 2018 Mar 10.
8
MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients.
Mol Cell Neurosci. 2016 Jul;74:10-7. doi: 10.1016/j.mcn.2016.02.002. Epub 2016 Feb 24.
9
Molecular and Functional Characterization of Histone Deacetylase 4 (HDAC4).
Methods Mol Biol. 2016;1436:31-45. doi: 10.1007/978-1-4939-3667-0_4.
10
Inflammation leads through PGE/EP signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes.
EMBO Mol Med. 2018 Jul;10(7). doi: 10.15252/emmm.201708536.
引用本文的文献
1
PGC-1α-mediated angiogenesis prevents pulmonary hypertension in mice.
JCI Insight. 2023 Sep 8;8(17):e162632. doi: 10.1172/jci.insight.162632.
2
Histone Methyl Transferase G9a/GLP-A Novel Avenue in Pulmonary Arterial Hypertension Treatment?
Am J Respir Cell Mol Biol. 2023 May;68(5):475-477. doi: 10.1165/rcmb.2023-0028ED.
3
Regulatory T Cell-Related Gene Indicators in Pulmonary Hypertension.
Front Pharmacol. 2022 May 31;13:908783. doi: 10.3389/fphar.2022.908783. eCollection 2022.
4
MEF2 (Myocyte Enhancer Factor 2) Is Essential for Endothelial Homeostasis and the Atheroprotective Gene Expression Program.
Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1105-1123. doi: 10.1161/ATVBAHA.120.314978. Epub 2021 Jan 7.
5
Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Sci Rep. 2020 Jul 30;10(1):12864. doi: 10.1038/s41598-020-69737-x.
6
Band on the run: insights into right ventricular reverse remodelling.
Cardiovasc Res. 2020 Aug 1;116(10):1651-1653. doi: 10.1093/cvr/cvaa091.
7
Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension.
Sci Rep. 2019 Dec 9;9(1):18623. doi: 10.1038/s41598-019-55053-6.
8
Takayasu arteritis risk locus in represses the anti-inflammatory gene through chromatin looping and recruiting MEF2-HDAC complex.
Ann Rheum Dis. 2019 Oct;78(10):1388-1397. doi: 10.1136/annrheumdis-2019-215567. Epub 2019 Jul 17.
9
MEF2 and the Right Ventricle: From Development to Disease.
Front Cardiovasc Med. 2019 Mar 28;6:29. doi: 10.3389/fcvm.2019.00029. eCollection 2019.
10
The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):334-354. doi: 10.1177/1074248419829172. Epub 2019 Feb 17.
本文引用的文献
1
Endothelial Myocyte Enhancer Factor 2c Inhibits Migration of Smooth Muscle Cells Through Fenestrations in the Internal Elastic Lamina.
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1380-1390. doi: 10.1161/ATVBAHA.117.309180. Epub 2017 May 4.
2
Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.
Am J Respir Crit Care Med. 2017 Jan 15;195(2):167-178. doi: 10.1164/rccm.201604-0886PP.
3
Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension.
Circulation. 2015 Jan 13;131(2):190-9. doi: 10.1161/CIRCULATIONAHA.114.013339. Epub 2014 Oct 21.
4
A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension.
Circ Res. 2015 Jan 2;116(1):56-69. doi: 10.1161/CIRCRESAHA.115.303910. Epub 2014 Oct 6.
5
Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension.
Am J Respir Cell Mol Biol. 2014 Mar;50(3):647-53. doi: 10.1165/rcmb.2013-0135OC.
6
Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development.
Circ Res. 2013 Jun 21;113(1):22-31. doi: 10.1161/CIRCRESAHA.113.301324. Epub 2013 Apr 19.
7
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
Nat Chem Biol. 2013 May;9(5):319-25. doi: 10.1038/nchembio.1223. Epub 2013 Mar 24.
8
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Cancer Res. 2013 Feb 15;73(4):1386-99. doi: 10.1158/0008-5472.CAN-12-2730. Epub 2012 Nov 13.
9
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.
Nature. 2010 May 27;465(7297):483-6. doi: 10.1038/nature09002.
10
MEF2: a central regulator of diverse developmental programs.
Development. 2007 Dec;134(23):4131-40. doi: 10.1242/dev.008367. Epub 2007 Oct 24.
Zotero 插件